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Abstract
Reactive oxygen species (ROS) and oxidative stress have long been linked to aging and diseases 
prominent in the elderly such as hypertension, atherosclerosis, diabetes and atrial fibrillation (AF). 
NADPH oxidases (Nox) are a major source of ROS in the vasculature and are key players in 
mediating redox signalling under physiological and pathophysiological conditions. In this review, 
we focus on the Nox-mediated ROS signalling pathways involved in the regulation of ‘longevity 
genes’ and recapitulate their role in age-associated vascular changes and in the development of 
age-related cardiovascular diseases (CVDs). This review is predicated on burgeoning knowledge 
that Nox-derived ROS propagate tightly regulated yet varied signalling pathways, which, at the 
cellular level, may lead to diminished repair, the aging process and predisposition to CVDs. In 
addition, we briefly describe emerging Nox therapies and their potential in improving the health of 
the elderly population.
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INTRODUCTION
Aging is the predominant risk factor in cardiovascular diseases (CVDs) [1] and the latest 
statistics show that of the 83.6 million American adults with some form of CVD, 42.2 
million are estimated to be ≥60 years of age [2]. Currently, CVD is the leading cause of 
death in the U.S.A.; approximately 66 % of CVDs occurring in people 75 years of age or 
more [2]. It is projected that by 2030 nearly 40.5 % of the U.S.A. population will have more 
than one type of CVD [3]. With increasing age, clinical manifestations and prognosis of 
vascular diseases worsen as a result of molecular changes associated with the aging process, 
often similar to specific pathophysiological changes observed in disease. Moreover, aging is 
a cumulative multifactorial process and not linked to a single cause. To date, multiple 
theories of biological aging are discussed within the literature, e.g. the ‘wear and tear’ 
theory, auto-immunity theory, programmed cellular theory, somatic mutation theory or 
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homoeostatic theory have been discussed previously [4,5]. However, many of these 
viewpoints share ‘oxidative stress’ as the common denominator in aging. The free radical 
theory of aging suggests that accumulated damage caused by free radicals and reactive 
oxygen species (ROS) accelerates the aging process [6]. Although there is still considerable 
debate that a single theory can explain the aetiology of aging, the free radical theory of aging 
still draws considerable attention and intrigue. It is now generally accepted that superoxide 
anion and other ROS can exert beneficial/protective effects under normal conditions, via the 
promotion of antioxidant enzyme expression and through adaptive cellular signalling 
responses. Harmful effects, on the other hand, are the result of aberrant redox signalling and 
direct damage to biologically sensitive targets. Typically, this oxidative damage results in a 
pro-senescent phenotype, which is one mechanism explaining biological aging [7,8]. 
Although senescence can be triggered by telomere attrition, mitogen-mediated extracellular 
signalling or decreased replicative capacity, oxidative stress remains a prominent instigator 
of this phenotype [9–11]. While associated, biological aging, senescence and longevity are 
distinct processes. Therefore, an improved understanding of the biology governing age-
related decline of cellular function and homoeostasis is imperative.
Furthermore, although differences in cardiovascular function between young and old have 
been extensively described in the literature, the majority of the in vivo studies related to 
CVD have been performed in young animals. Hence, it is important to understand how ROS 
contributes to aging and is, in turn, a critical contributor to age-related diseases. Perspectives 
on the role of NADPH oxidase (Nox)-derived ROS in aging and the potential signalling 
mechanisms that underlie these age-related changes as well as how they relate to CVD in 
older population are the focus of the present review. The potential for currently available 
Nox therapeutic strategies to intervene in the cellular aging process and thereby slow the 
onset of age-related CVD are also discussed.
OXIDATIVE STRESS THEORY, AGING AND NADPH OXIDASES
The free radical theory of aging, when first proposed by Harman [6], suggested that 
longevity is governed by the production of endogenous oxygen radicals in cells, resulting in 
a pattern of cumulative damage in a random and indiscriminate manner. This theory, 
therefore, implied that an overall reduction in oxidative stress, either by reducing the pro-
oxidant load or by increasing antioxidant defences or both, protects against aging and 
increases lifespan.
Although cellular defences [including catalase, Cu/Zn superoxide dismutase (SOD1) and 
glutathione peroxidases (Gpxs)] combating oxidative damage are normally plentiful, they 
are not entirely effective, as oxidatively damaged macromolecules still accumulate with 
biological aging [12]. There is supporting evidence from studies in Caenorhabditis elegans 
and Drosophila, two well-established models to study aging, which revealed that decreased 
ROS production may improve resistance to oxidative stress and therefore increase lifespan 
[13,14]. In mammals, however, studies are largely correlative, based on findings of increased 
oxidatively damage DNA and/or proteins in aged individuals [15]. Moreover, studies 
performed in vertebrate animals using transgenic and knockout mouse models [e.g. SOD, 
Gpx, thioredoxin 2 (Trx2) and catalase] provide conflicting evidence regarding effects on 
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lifespan or longevity [16–24]. It is worth noting that antioxidant enzyme systems are not the 
only factors involved in cellular homoeostasis. Other enzymes, such as Noxs and 
myeloperoxidase (MPO), historically assumed to generate ROS for destructive purposes (i.e. 
in host defence), are now known to serve as important signal-transducing enzymes. Their 
activation is elicited in response to a variety of growth factors, cytokines and G-protein-
coupled receptors [25–30]. ROS are also produced via a variety of other enzyme systems 
including xanthine oxidase (XO), cytochrome P450 and by uncoupling of nitric oxide (NO) 
synthase (NOS), yet Noxs appear to predominate in cellular ROS production. ROS have also 
emerged as locally produced in multiple cellular compartments including at the plasma 
membrane and within the mitochondrion, peroxisomes and the cytoplasm. Furthermore, 
basal ROS mediate important biological functions by regulating the activity of diverse 
intracellular signalling pathways involved in growth, apoptosis, survival, metabolism and 
migration [26–28,31–34]. It stands to reason therefore that specific signal transduction by 
any one Nox in a particular cell is a consequence of its co-localization with upstream and 
downstream effectors of each pathway. A protective role for ROS nothwith-standing, a wide 
array of studies suggests that ROS participate in biological aging and age-related CVDs such 
as atherosclerosis, hypertension, stroke and atrial fibrillation (AF) [35–51].
Despite evidence suggesting a causal link between aging and disease, little is known 
regarding the molecular mechanisms that dictate age-related processes and their association 
with diseases. A number of studies, at both the cellular and the organismal levels, have 
reported increased lifespan with increased resistance to oxidative stress. However, whether 
this may be attributed to a common signal transduction pathway that regulates aging and 
response to oxidative stress or a variety of pathways is yet to be determined. Logic informs 
us that multiple pathways are most likely involved. Figure 1 illustrates a few of the 
important signalling pathways implicated in the process of aging. Indeed, one mechanistic 
link between aging and oxidants comes from studies showing that mice lacking p66Shc have 
a ~30 % increase in lifespan, which is correlated to reduced intracellular ROS. These studies 
also showed that oxidative regulation of p53 and FKHRL1 [forkhead-box protein O3 
(FOXO3)] is mediated by p66Shc [52–55]. Other proteins and pathways linked to aging are 
SIRT1 (sirtuin 1; mammalian homologue of Sir2 protein found in lower organisms) [56–59], 
Klotho [60–62], AMP-activated protein kinase (AMPK) [63], protein skinhead 1 (SKN-1) 
[homologue of nuclear respiratory factor 1] [64], Clock 1 (clk-1) [65,66], insulin/insulin-like 
growth factor (IGF)-1 signalling [67] and mammalian target of rapamycin (mTOR) 
signalling [68,69].
Mammalian NADPH oxidase
The NADPH oxidase family of enzymes are considered the ‘professional’ enzymatic source 
of ROS in vascular cells and are therefore known to be a major contributor to vascular 
dysfunction and disease [43,44,47,48,70–76]. In this regard, Nox isozymes plausibly play a 
prominent role in age-related susceptibility to vascular occlusive diseases such as coronary 
artery disease (CAD) and peripheral artery disease (PAD), hypertension and diabetes, 
through redox signalling pathway activation [29,30,45,46,49,50,77–86]. The structure and 
function of Nox isozymes are complex and more thoroughly reviewed elsewhere 
[43,44,47,48,74,87]. It is the aim of the current review to outline their role in ROS 
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production and their ability to contribute to the aging process. In brief, the Nox family 
consists of seven isoforms [Nox1–5 and Duox1–2 (dual oxidase 1–2)], of which Nox1, 
Nox2, Nox4 and Nox5 are known to be expressed in human vascular tissue [88]. Moreover, 
Nox enzymes are varied in their cellular expression and are identified by their catalytic core, 
and extensive evidence demonstrates their contribution to vascular dysfunction [77]. 
Importantly, Nox1, Nox2 and Nox4 isoforms, but not Nox5, require the smaller membrane-
bound p22phox component for membrane stabilization and activity [89]. Nox1 and Nox2 are 
regulated by sometimes distinct, otherwise interchangeable, cytosolic components loosely 
termed as activators or organizers, which are generally recruited to the membrane 
components following cellular stimuli to assemble an active Nox [90–92]. To date, Nox2 
remains the most extensively studied family member in a variety of physiological and 
pathophysiological signalling pathways. The active Nox2 enzyme complex comprises the 
catalytic Nox2 subunit in association with p22phox to form the cytochrome B558 complex, 
p47phox (organizer), p67phox (activator), p40phox and the small Rho-family GTP-binding 
protein Rac1/2 [30]. Arguably, Nox2 is the most widely distributed of the isoforms, present 
in phagocytes, heart, lung and the vasculature, among multiple other tissues, and is 
suggested to be increased in aging vascular cells [93]. Similarly, the active Nox1 system is 
composed of the Nox1 catalytic subunit, p22phox and in its canonical subunits NoxO1 
(p47phox homologue), NoxA1 (p67phox homologue) and Rac1/2 [94]. Nox1 is highly 
expressed in the colon, but is currently also known to be present in the heart, lungs and 
blood vessels. In contrast, the Nox4 system is composed of the Nox4 catalytic subunit and 
p22phox, with the only other known associated protein described for its activity being 
Poldip2 [95]. It is widely held that Nox4’s activity is regulated transcriptionally, and, 
interestingly, it is up-regulated in aging VSMCs (vascular smooth muscle cells) [96]. 
Incidentally, Nox4 is expressed in all three main vascular cell types: the endothelial cell, 
smooth muscle cell and fibroblast. Another distinct feature of Nox4 compared with other 
Nox is that it is constitutively active and appears to preferentially produce H2O2 over 
superoxide anion. It has been suggested that Nox4 may act as an oxygen sensor [97]. 
Finally, Nox5, which does not require p22phox for membrane stabilization, is regulated by 
calcium binding through EF-hand motifs [98]. Although Nox enzymes have been implicated 
to play a crucial role in several signalling pathways, a lack of crystal structure for Nox 
isoenzymes as well as structural similarities among Nox family members have confounded 
progress towards the generation of specific antibodies and small-molecule inhibitors. 
Therefore, when implicating Nox isoenzymes in any study, it is critical that key positive 
controls are used to account for antibody limitations, as is discussed by Baniulis et al. [99]; 
namely neutrophil homogenates for Nox2, colon homogenates for Nox1, kidney 
homogenates for Nox4 or heterologous overexpression cell systems. In addition, mRNA 
analyses [78,100,101] are highly recommended to corroborate changes detected at the 
protein level.
ROS production by activated NADPH oxidase is mediated by a wide variety of factors 
including mechanical forces, environmental factors (e.g. hypoxia) and cytokines and 
hormones such as angiotensin II (AngII), aldosterone, endothelin-1 (ET-1), platelet-derived 
growth factor (PDGF), TGFβ (transforming growth factor β) and TNFα (tumour necrosis 
factor α) [71,75,82,102–106]. In the light of this broad and often deleterious role for Nox, 
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the quest for efficacious and isoform-selective Nox inhibitors is expected to come into even 
greater focus in Nox-related disease research, i.e. advances in biochemical characterization 
and ROS detection agents are anticipated to facilitate viable therapy development [107–110]. 
As Nox-derived ROS are an important culprit in the free radical theory of aging, selective 
inhibition is anticipated to be a viable therapeutic strategy in age-related disease, and the 
roles of Nox in the aging process are expected to be explored in further depth in the coming 
years as a consequence of an increasingly aging population in the developed world.
ROLE OF ROS SIGNALLING IN PROTEINS INVOLVED IN AGING
p66Shc adaptor protein
p66Shc protein is one of the three isoforms encoded by the mammalian Shc locus. Shc 
proteins (p66Shc, p52Shc and p46Shc) are cytoplasmic signal transducers involved in the 
transmission of mitogenic signals from activated receptors to Ras proteins. Although the 
three splice variants carry similar structural domains, p66Shc contains an additional collagen-
homology region in the N-terminus, allowing p66Shc to function in intracellular pathway(s) 
that regulate ROS metabolism and apoptosis [52,111]. Whereas activation with growth 
factors (such as epidermal growth factor receptor, EGF) induce tyrosine phosphorylation and 
Ras activation, environmental stress factors, such as H2O2 or UV irradiation, induce serine 
phosphorylation on p66Shc through protein kinase Cβ (PKCβ) [112] and JNK [113], causing 
increased apoptosis. Deletion of p66Shc protein was shown to reduce oxidative stress and 
high-fat-induced atherogenesis and increase cellular resistance to apoptosis as well as life 
expectancy by 30 % [52,53]. Since that study, several others have reported a link between 
the redox regulation of p66Shc protein and downstream signalling via p53/p21cip and 
FOXO3 to mechanisms that modulate longevity [54,55]. Increasing evidence supports that 
oxidative stress-induced serine phosphorylation of p66Shc leads to mitochondrial 
accumulation of p66Shc, where it binds to cytochrome c via the CH2–PTB domain. This, in 
turn, leads to redox activation and the transfer of electrons to O2, leading to generation of 
mitochondrial H2O2. Increased mitochondrial H2O2 results in opening of permeability 
transition pore (PTP) leading to increased swelling and apoptosis [112,114]. Pinton et al. 
[112] showed that oxidative-stress-mediated activation of PKCβ leads to phosphorylation of 
p66Shc, which effects translocation of p66Shc to the mitochondrial membrane. This process 
is mediated by prolyl isomerase 1 (Pin1). Another study describing a mechanistic pathway 
underlying the apoptogenic effect of p66Shc suggested that UV-irradiation-induced 
dissociation of p66Shc and mitochondrial heat-shock protein (Hsp) 70 results in decreased 
membrane potential and increased trans-mitochondrial permeability, leading to apoptosis 
and decreased lifespan [115]. Many other studies strengthen the link between p66Shc, 
mitochondrial oxidative damage and aging by providing evidence of phosphorylation of 
protein kinase B/Akt, up-regulation of p53-dependent apoptosis, inactivation of FOXO3a 
and suppression of MnSOD [54,55,116,117]. Most of those studies have linked 
mitochondrial ROS as a causal source of p66shc-mediated oxidative damage. Only one 
previous study showed that NADPH oxidase-dependent superoxide production in 
macrophages of p66Shc-knockout mice was attenuated by 40 % [118]. In that study, Tomilov 
et al. [118] demonstrated that the deficit in NADPH oxidase-dependent ROS production was 
independent of expression levels of Nox2 subunits (i.e. Rac1/2, p40phox, p47phox, p67phox, 
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p22phox and gp91phox), but rather governed by reduced phosphorylation and membrane 
translocation of p47phox (organizing subunit of Nox2 complex) in macrophages isolated 
from p66Shc-knockout mice, as well as in p66Shc siRNA-transfected RAW264.7 
macrophages. The authors also observed decreased activation of PKCδ, Akt and 
extracellular-signal-regulated kinase (ERK) in the p66Shc mutants, suggesting that a Shc-
dependent defect in signalling via PKCδ, Akt and ERK activation contributed to the defect 
in p47phox phosphorylation and Nox2-dependent superoxide production. With that said, 
these studies, taken together, suggest the potential for p66Shc/Nox2 signalling pathways in 
oxidative-stress-mediated effects on inflammation, atherosclerosis and longevity.
p53/p21 pathway
The redox-sensitive transcription factor p53 functions as a longevity-associated gene due to 
its strong tumour-suppressor activity [119]. In unstressed mammalian cells, p53 has a short 
half-life and is maintained at low levels by ubiquitination catalysed by Mdm2 [120,121], 
COP1 (constitutively photomorphogenic 1) [122] and Pirh2 (p53-induced protein with a 
RING-H2 domain) [123]. The stability and activity of p53 are subject to diverse covalent 
post-translational modifications such as ubiquitination [124,125], phosphorylation [126], 
acetylation [127], NEDDylation [128], SUMOylation [129] and methylation [130]. Among 
these post-translational modifications, ROS have been implicated in the phosphorylation of 
p53 mediated through p38α MAPK (mitogen-activated protein kinase) [131,132] and Polo-
like kinase 3 (Plk3) [133]. Moreover, p53 itself is redox-active due to the presence of 
cysteines that contain redox-sensitive thiol groups [134]. In human p53, two clusters of 
cysteines in the DNA-binding domain exist and these are essential for the specific binding of 
p53 to its consensus sequence for transcription of p53-dependent genes [135,136]. 
Importantly, the role of p53 in premature aging is evident from several mouse studies where 
persistent low-level activation and increased expression, by ROS signalling, telomere 
erosion or DNA damage, promotes senescence or irreversible cell cycle arrest [137–139]. In 
turn, vascular cell senescence is one proposed mechanism surrounding unstable 
atherosclerotic plaque progression [140]. The ability for p53 to control senescence is 
consistent with its function to restrain vascularized tumour development, but the precise role 
for maintenance of longevity requires further investigation [141]. Whereas ROS are 
demonstrated to promote p53 activation, p53 has also been shown to enhance ROS 
signalling, presumably via up-regulation of the p67phox subunit as identified previously 
[142]. However, p53 is also known to participate in the induction of vascular cell apoptosis, 
which could enhance disease progression [34,143]. But, as p53 also promotes the expression 
of a number of antioxidant genes, it remains to be clearly demonstrated whether this could 
account for p53’s ability to control oxidative stress and therefore dictate whether a cell 
becomes apoptotic or senescent [144,145]. Induction of senescence by p53 is associated 
with the regulation of p53-dependent genes which participate in cell cycle arrest. Of these, 
p21cip was identified as the key factor governing the switch to a senescent phenotype. p21cip 
or cyclin-dependent kinase inhibitor 1, functions to inhibit cell cycle progression by placing 
a block on the G1- to S-phase transition of the cell cycle [146,147]. Therefore, activation of 
p53 by ROS and downstream up-regulation of p21cip appears to play a key role in the 
adaptive response of the vasculature in disease. This is evident in a nutrient deprivation 
model in vitro where serum-starved human endothelial cells underwent p53/p21cip-
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dependent cell cycle arrest via Nox2-derived superoxide anion [148]. Furthermore, Nox1- 
and Nox4-derived ROS were demonstrated to play a role in lung fibroblast senescence via 
p53-dependent p21cip up-regulation following matricellular CCN1 exposure [149]. 
Moreover, Kodoma et al. [150] support these findings wherein Nox1- and Nox4-derived 
ROS play central roles in p53 activation, leading to premature fibroblast senescence. In that 
study, siRNA against Nox1 and/or Nox4 inhibited Ras-induced premature senescence. This 
was the first piece of evidence that suppression of selective Nox isoforms could be 
instrumental in the maintenance of vascular longevity. Finally, redox activation of p53/p21cip 
signalling leading to senescence is evident in murine models of hypertension [151,152], 
diabetes [153,154], atherosclerosis [155,156] and pulmonary hypertension [121,157].
Klotho
The Klotho gene was first identified by Kuro-o et al. [60] in 1997, as a putative anti-aging 
gene, since Klotho-null mice displayed phenotypes resembling premature human aging, 
including vascular calcification, pulmonary emphysema, skin atrophy, muscle atrophy, 
osteoporosis, arteriosclerosis and cognitive impairment, among others [60,158]. Several 
studies have linked Klotho’s influences to intracellular signalling pathways involved in 
oxidative stress responses and aging via inhibition of IGF-1 [61,62,159] and p53/p21cip 
[160] and activation of FOXO3 [62]. Klotho is a transmembrane protein that functions as a 
FGF23 co-receptor with FGFR and is critical in maintaining proper calcium, phosphate and 
vitamin haemostasis [60]. Although the Klotho gene is mainly expressed in kidneys and the 
choroid plexus of the brain, the secreted soluble form may cause paracrine effects in distant 
organs. Recent studies show that Klotho exerts a protective effect against oxidative damage 
associated with age-related and retinal and neurodegenerative disorders, such as age-related 
macular degeneration (AMD) and Alzheimer’s disease [161,162]. These studies suggest that 
binding of the secreted Klotho protein to the membrane results in phosphorylation and 
translocation of FOXO3a to the nucleus, leading to transcriptional activation of MnSOD and 
peroxiredoxin-2 (Prx2), and thereby increasing resistance to oxidative stress [62]. Klotho is 
also shown to be protective of arterial calcification by preventing differentiation of VSMCs 
to an osteoblast-like phenotype and by restoring FGF23 signalling [163,164]. Another study 
by Saito et al. [165] showed the involvement of ROS and iron metabolism in AngII-
mediated down-regulation of renal Klotho expression. Although Klotho is not known to be 
expressed in blood vessels but is a circulating hormone, it reportedly protects against 
endothelial dysfunction in age-associated disorders through endothelium-derived NO 
production [166–169]. The role of Klotho in age-related CVD was initially based on the 
development of atherosclerosis in Klotho-deficient mice [60]. Since then it has been 
suggested that Klotho may have a protective role in the cardiovascular system through 
endothelium-derived NO production and regulation of angiogenesis [166–168]. Subsequent 
population-based studies in humans have identified a functional variant of Klotho, i.e. KL-
VS, which is associated with the early-onset occult CAD [170] and cardiovascular risk 
factors such as high-density lipoprotein cholesterol, high blood pressure and stroke [171]. 
Although a number of studies show that Klotho protein is protective under oxidative stress, 
the precise mechanisms underlying these phenomena are not completely understood [172]. 
A study recently showed that the protective effect of Klotho against oxidative damage is a 
consequence of increased endogenous antioxidant capacity (increased SOD2 and 
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thioredoxin) via increased nuclear factor erythroid-derived 2-related factors 1 and 2 (Nrf1/2) 
transcriptional activity [173,174]. In a study, Wang et al. [175] showed that direct delivery of 
Klotho suppresses AngII-induced Nox2-derived superoxide anion production and oxidative 
damage and attenuates apoptosis via the cAMP/PKA pathway in rat aortic smooth muscle 
cells (RASMCs). This study suggests the potential cross-talk between Klotho and Nox2 
signalling pathways in oxidative-stress-mediated effects on endothelial dysfunction, 
hypertension, atherosclerosis and lifespan.
IGF-1 pathway
The C. elegans homologue of IGF-1, daf-2, was one the early genes to be identified as a 
longevity-related gene [67]. IGF-1 is synthesized by almost all tissues and is involved in cell 
growth, differentiation and transformation processes. It is also well known that IGF-1 exerts 
pleiotropic effects by virtue of its binding to both IGF-1 receptor (IGF-1R) and insulin–
IGF-1 hybrid receptors [176]. Several studies have shown that oxidative stress such as that 
caused by H2O2 and AngII stimulates IGF-1 and IGF-1R, which is mediated by a tyrosine 
kinase-dependent redox-sensitive mechanism [177,178]. A number of studies in C. elegans, 
since the discovery of IGF-1 as a longevity-related gene, have shown that attenuation of 
IGF-1 signalling increases lifespan. This involves cross-talk with several other genes/
pathway(s) implicated in aging, such as FOXO transcription factor (daf-16) [179], heat-
shock transcription factor (HSF)-1 [180], SKN-1, an Nrf-like xenobiotic factor [64] and 
mTOR pathway. These transcription factors, in turn, modulate a diverse set of genes that act 
cumulatively to produce large beneficial effects on the lifespan of C. elegans. Indeed, 
mutations known to impair IGF-1R in several centenarian human cohorts strengthen the case 
that insulin/IGF-1 signalling is negatively associated with lifespan [181,182]. On the other 
hand, studies in rodents and humans have raised reservations regarding the role IGF-1 plays 
in aging. Studies show that mice deficient in IGF-1 die shortly after birth, whereas some that 
live to adulthood have retarded growth [183]. In humans, an age-related decline in endocrine 
IGF-1 levels is reported, and a large body of evidence suggests that IGF-1 improves 
cardiovascular function and is atheroprotective [184–187]. IGF-1 overexpression in the heart 
prevented myocardial cell death after infarction and reduced ventricular dilation, 
hypertrophy and diabetic cardiomyopathy via attenuation of p53 activation and AngII 
production, thereby leading to reduced ROS and cellular damage [188–191]. Another study 
showed that anti-atherogenic effects of IGF-1 infusion in the pro-atherogenic ApoE-
knockout mouse model occur via suppression of oxidative stress and up-regulation of 
vascular eNOS expression leading to increased NO bioavailability [187]. Csiszar et al. [192] 
reported that in Ames dwarf long-lived mice, low IGF-1 serum concentrations were 
associated with high oxidative stress in the vasculature and reduced eNOS expression, 
leading to endothelial dysfunction. More importantly, exogenous IGF-1 enhanced expression 
of antioxidant enzymes such as MnSOD, Cu/ZnSOD, Gpx1 in explants of mouse aortas and 
human coronary arterial endothelial cells [192]. In a study, Bailey-Downs et al. [193] 
showed that IGF-1-deficient mice were also lacking in Nrf-2 and Nrf-2-driven antioxidant 
genes, NAD(P)H:quinone oxidoreductase1 (NQO1) and heme oxygenase-1 (HMOX-1), 
thereby impairing the ability of vascular cells to respond to oxidative stress caused by high 
glucose, oxidized LDL (low-density lipoprotein) and/or H2O2. Endocrine IGF-1 deficiency 
in the vasculature promotes adverse vascular phenotype under disease states and results in 
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accelerated vascular impairments in aging [193]. Altogether, these studies suggest that 
IGF-1 has antioxidant-like effects.
Thus, it appears important to note that opposing effects of IGF-1 signalling are at work in 
different phases of the human life cycle. This disparity in IGF-1-mediated effects is probably 
a result of the difference between autocrine and paracrine effects of IGF-1. Interestingly, Li 
et al. [194] used the LID (liver IGF-1-deficiency) mouse model to examine the mechanism 
involved in IGF-1-deficiency-induced effect on cardiac aging. They showed that severe 
IGF-1 deficiency reduced aging-associated cardiac contractile dysfunction, prolonged 
relaxation and ablated intracellular Ca2+ dysfunction. Moreover, the IGF-1-deficiency-
elicited effects on cardiac aging were correlated with antagonism against aging-induced 
reduction in Akt, AMPK phosphorylation, Klotho and up-regulated p53 [194]. A similar 
study involving the response to a challenge with pro-oxidant paraquat in LID mice 
demonstrated that IGF-1 deficiency effectively enhanced resistance to oxidative-stress-
induced cardiac dysfunction, attenuated ROS and carbonyl production, ultimately resulting 
in improved survival rate against paraquat-induced mortality [195]. In experimental aortic 
abdominal constriction (AAC) studies in mice, liver-specific IGF-1 deficiency mitigated 
AAC-induced cardiac hypertrophy and contractile changes via attenuating AAC-induced 
Akt phosphorylation and glucose transporter 4 (GLUT4) up-regulation and rescuing down-
regulated miR-1 and miR-133a levels [196]. Therefore, whether reduced IGF-1 levels are 
negatively or positively correlated to age-associated decline in cardiovascular physiological 
functions is yet to be fully elucidated.
NOX IN AGING
Progressive anatomical, mechanical and biochemical changes occur in the heart as an 
adaptive response with increasing age. Aging is accompanied by an increase in arterial 
systolic pressure, reduced or maintained diastolic pressure, increased pulse pressure, aortic 
dilatation and wall thickening [197]. However, one of the major caveats in the study of aging 
and its effect on CVDs is that multifactorial changes that occur during the aging process are 
indistinguishable from vascular phenotypes such as endothelial dysfunction, increased 
collagen deposition, fibrosis and vessel remodelling presented in CVDs. In one of the early 
studies carried out in individuals who died from causes other than CVDs, it was reported 
that aging human hearts are characterized by an increase in the volume fraction of myocytes, 
myocyte loss, cellular hypertrophy and reduction in the ventricular mass. These cellular 
processes represent underlying causes for the onset of myocardial dysfunction and failure in 
the aging population [198]. Wang et al. [199] examined the involvement of Nox in age-
associated cardiac remodelling in a rodent model of aging and found that age-dependent 
increases in blood pressure, cardiomyocyte hypertrophy, coronary artery remodelling and 
cardiac fibrosis were associated with increased myocardial Nox2 activity. The increase in 
Nox2-dependent ROS were accompanied by increased renin–angiotensin–aldosterone 
system (RAAS) activation in the myocardium, increased expression of connective tissue 
growth factor (CTGF) and TGFβ1 and a significant activation of matrix metalloproteinase 
(MMP)-2 and membrane type-1 (MT1)-MMP, leading to age-associated cardiac remodelling 
[199]. It is widely acknowledged that Nox4 is localized to the mitochondria of many 
different cell types and that mitochondrial oxidative stress promotes aging. In this regard, 
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Ago et al. [200] reviewed the role of mitochondrial Nox4 in the aging process of the heart. It 
was speculated that oxidant stress in mitochondria builds when antioxidants are unable to 
counteract the ROS produced by Nox4, triggering the aging process of the heart. It is 
tempting, therefore, to speculate that Nox4 may be the initiator of mitochondrial ‘stress’ and 
oxidant production or vice versa. However, Nox4 has been identified to be beneficial against 
disease-induced cardiac dysfunction and hypertrophy and is therefore assumed to be 
‘protective’ [44]. Whatever the relationship, it appears that these two very important sources 
of ROS could be linear in their role. Taken together, these studies suggest that NADPH 
oxidase-derived ROS play a pivotal role in the process of aging and age-related 
cardiovascular changes, whether these are in conjunction with or independent of the 
mitochondrion. However, despite their importance in vascular function and disease, very few 
studies provide mechanistic insight into the role of Nox in the aging process. Figure 2 
depicts the proposed effects of Nox-derived ROS on redox-sensitive longevity signalling in 
the vessel wall.
NOX IN AGE-ASSOCIATED CVD
Atherosclerosis
Age is an important independent risk factor for the development of atherosclerosis, which 
persists even when other risk factors such as hypertension, diabetes, smoking and LDL 
cholesterol levels are controlled. This may be attributable to characteristic features of aging 
vessels, including reduced medial VSMC number, increased collagen deposition and 
breakdown of the elastic lamellae, which collectively can lead to medial thickening and 
vessel remodelling. These changes are likely to further promote increased extracellular 
matrix and vascular stiffness, subsequently leading to systolic hypertension. Adhesion and 
recruitment of pro-inflammatory molecules, also a result of luminal and lamellae damage, 
logically result in lipid accumulation and foam cell formation following monocyte 
infiltration [201–204]. As a consequence, the effects of atherosclerosis are superimposed on 
normal aging of the underlying vessel and therefore it is of utmost importance to unravel the 
molecular mechanisms involved. Towards that end, it is now generally agreed that elevated 
vascular ROS triggers an atherosclerotic process by oxidatively modifying lipoproteins 
causing activation of pro-inflammatory signalling and endothelial dysfunction resulting in 
further elevated oxidative stress. Pro-oxidant stimuli further result in reduced cell 
proliferation, irreversible growth arrest and apoptosis, elevated DNA damage, epigenetic 
modifications and telomere shortening, all of which are distinguishing features of cellular 
senescence as well as accelerated vascular aging associated with atherosclerosis [205]. Many 
of these cellular events are modulated by ROS-mediated signal transduction catalysed by 
Nox [74,206]. Because all cells comprising the lining and vessel wall harbour one or the 
other isoform of Nox, singularly or collectively they provide a mechanism of localized or 
paracrine release of ROS, which can influence redox-sensitive signalling pathways with 
fundamental effects on atherogenesis. One of the first points of evidence for NADPH 
oxidase-derived superoxide anion as a clinical risk factor for atherosclerosis was reported by 
Guzik et al. [71]. This study, based on clinical samples, showed that NADPH oxidase is the 
main source of superoxide production in human saphenous veins, which is associated with 
impaired NO-mediated endothelial function and increased atherosclerotic risk factors. Two 
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other studies identified the cellular sources of intracellular superoxide anion production 
within atherosclerotic and non-atherosclerotic human coronary arteries and found increased 
expression of p22phox, Nox2 (gp91phox) and Nox4 in the shoulder regions of the plaque, 
whereas expression of Nox1 was reduced [72,78,207]. Interestingly, Sorescu et al. [78] 
noted a strong association of Nox2 to plaque macrophage content and Nox4 to SMCs and 
advanced fibrocellular plaques, but not in more advanced atherosclerotic lesions [78]. More 
importantly, intense ROS in the plaque regions corresponded to increased expression of 
p22phox and Nox2, implicating NADPH oxidase-derived ROS in plaque rupture [78]. 
Further, Barry-Lane et al. [79] demonstrated the role of p47phox subunit in the development 
of atherosclerosis and showed that p47phox−/−/ApoE−/− mice have significantly lower aortic 
superoxide production, decreased proliferative response to growth factors and lesion 
formation compared with ApoE−/− mice. A later study by the same group showed that the 
atheroprotective effect of p47phox deficiency in ApoE-null mice was a result of a decrease in 
Nox2-derived ROS from monocytes/macrophages that reduced levels of oxidized LDL as 
well as from that of vessel wall cells, which attenuated the expression of cellular adhesion 
molecules [208]. Several studies further strengthen the involvement of Nox2 in 
atherogenesis. Judkins et al. [209] demonstrated that Nox2 expression was up-regulated in 
the aortic endothelium of ApoE−/− mice, before the appearance of lesions. They also showed 
that the absence of Nox2 in Nox2−/y/ApoE−/− mice was manifested by a reduced lesion area 
in the descending aorta by 50 % and was associated with decreased aortic ROS and 
increased NO bioavailability [209]. These studies provide a strong rationale for Nox-
dependent ROS as potential players contributing to premature aging of the vasculature via 
propagation of atherosclerosis.
Previously, it was reported that an endothelium-specific increase in Nox2-derived superoxide 
anion production is sufficient to increase macrophage recruitment and endothelial cell 
activation, leading to an increased atherosclerotic plaque initiation. However, this early event 
does not alter the progression of atherosclerosis [210]. Sheehan et al. [80] investigated the 
role of Nox1-smooth muscle cell component in atherogenesis and demonstrated that deletion 
of Nox1 reduced diet-induced lesion formation by 28 %, decreased macrophage infiltration 
and ROS levels compared with ApoE−/− mice. They showed that loss of Nox1 attenuated 
cell proliferation and increased collagen content within the neointima following carotid 
ligation. A greater reduction in lesion formation in ApoE/Nox2 double null mice observed in 
previous studies compared with Nox1−/y/ApoE−/− was explained by the absence of Nox1 in 
circulating cells [80]. These studies linked the increased expression of NADPH oxidase and 
intracellular superoxide anion production to oxidative modification of LDL and plaque 
instability via superoxide anion-induced expression of matrix-degrading proteases, such as 
MMP-2 and MMP-9 as well as associated SMCs and endothelial dysfunction. Additional 
evidence comes from a study showing the involvement of Nox1-derived ROS in diabetes 
mellitus-induced atherosclerosis. That study demonstrated that deletion of Nox1 reduced the 
development of aortic atherosclerosis in the diabetic ApoE−/− mice. This decrease in 
atherosclerosis was associated with reduced ROS formation, attenuation of chemokine 
expression, vascular adhesion of leucocytes, macrophage infiltration and reduced expression 
of pro-inflammatory and profibrotic markers [211].
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Not much is known regarding the role of Nox5 in atherosclerosis, primarily because of the 
limitation posed by Nox5’s absence in rats and mice. However, Guzik et al. [81] showed that 
expression of Nox5 is dramatically increased in atherosclerotic human coronary artery 
vessel wall which was associated with a 7-fold increase in calcium-dependent NADPH 
oxidase activity. Interestingly, Nox5 was localized to the endothelial cells in the early lesions 
and in the smooth muscle layer in advanced lesions [81]. Supporting evidence comes from a 
study showing that endothelial Nox5 is activated by AngII and ET-1 through Ca2+/
calmodulin-dependent and Rac-1-independent mechanisms, leading to increased ROS 
generation and ERK1/2-regulated growth and inflammatory signal transduction associated 
with endothelial dysfunction and vascular pathologies [212]. Nevertheless, the affected 
signal transduction pathways intertwining vascular aging and atherogenesis are poorly 
understood and are largely derived from studies on cellular senescence. ROS-mediated 
oxidative DNA damage is known to promote cellular senescence, which occurs both in the 
mitochondrial DNA and in the nuclear DNA, as well in both telomeric and non-telomeric 
regions of VSMC and macrophages in plaques [73,213]. Other than directly causing DNA 
damage, ROS-induced activation of p53 has been shown to promote DDR (DNA damage 
recognition and repair) and reduce the expression of the IGF-1R in VSMCs as well as the 
subsequent Akt survival signals [214]. Since both p53 and IGF-1 have been associated with 
longevity, signal transduction by these molecules might be responsible for NADPH oxidase-
mediated damage in atherosclerosis.
Hypertension
Hypertension is one of the most common diseases in the elderly. The prevalence of 
hypertension increases markedly with advancing age, primarily a result of elevations in 
blood pressure attributed to alterations in the structure, function and rigidity of vessel wall 
[215], as well as from a shift in control by the autonomic nervous system [216]. Several 
studies have shown that aging and hypertension are associated with the impairment of 
endothelium-dependent vascular relaxation and endothelial dysfunction. Both are known to 
increase the risk of cardiovascular and cerebrovascular diseases [71,75,217,218]. Oxidative 
stress is well established as a key regulator of age-induced endothelial dysfunction and 
RAAS. These influence the sympathetic and parasympathetic arms of the autonomic nervous 
system and promote hypertension. Moreover, it is well known that RAAS activation may 
itself potentiate oxidative stress [29,70]. Several clinical and animal model studies of 
hypertension have shown that increased NADPH oxidase-derived ROS is associated with 
endothelial dysfunction [76,102,103,105]. Zalba et al. [102] showed that endothelium-
dependent relaxation in response to acetylcholine was significantly attenuated in 30-week-
old compared with 16-week-old hypertensive rats. This impaired NO-dependent relaxation 
in AngII-mediated hypertension was linked to increased NADPH oxidase activity and 
expression of p22phox mRNA [102]. Another study of aging in a spontaneously hypertensive 
rat (SHR) model showed that RAAS attenuation in vivo by temocaprilat, hydralazine and 
olmesartan reversed age-related advanced cardiac hypertrophy due to suppression of cardiac 
oxidative stress by attenuating the expression of Nox2 oxidase components, p22phox, 
p47phox and Nox2 [219]. Another study demonstrated the role of MAPK-activated protein 
kinase 2 (MK2) in AngII-induced hypertension. Ebrahimian et al. [82] showed that MK2, 
which is a direct downstream target of p38 MAPK, mediates an AngII-induced increase in 
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Nox2-dependent superoxide production and activation of pro-inflammatory molecules 
through up-regulation of the p47phox subunit of NADPH oxidase and suppressed antioxidant 
enzyme catalase. The AngII-mediated up-regulation of MK2 resulted in a vicious cycle that 
potentiated inflammatory responses to AngII and led to increased VSMC proliferation [82]. 
Other than Nox2, several studies have demonstrated a role for Nox1 in systemic 
hypertension. Using transgenic mice overexpressing Nox1 in the smooth muscle cells, 
Dikalova et al. [220] provided a causal link between Nox1-derived superoxide production 
and increased systolic blood pressure and aortic hypertrophy in response to AngII. Matsuno 
et al. [83] generated Nox1−/y mice and showed that Nox1 in AngII-mediated hypertension 
underlies the pressor response. Similar studies showed that lack of Nox1 attenuated AngII-
induced ROS generation and Ca2+ signalling in VSMCs and Nox1-derived ROS regulated 
cell-surface expression of AT1R (AngII type 1 receptor) through mechanisms involving 
caveolin phosphorylation [221]. Although all the above studies suggest that hypertension, 
NADPH oxidase-derived ROS and oxidative stress are linked, none of them specifically 
examine the so-named longevity genes in hypertension. Wang and Sun [222] studied the role 
of Klotho in the pathogenesis of hypertension. In this study, they showed that Klotho gene 
delivery decreased aortic Nox2 expression and NADPH oxidase activity in SHRs, whereas 
renal expression of NOS, Nox1 and Nox4 remained unaltered. Further mechanistic studies 
delving into signalling that confer specificity of Nox inhibition by Klotho in systemic 
hypertension are warranted. Similarly, the role of Nox in redox signalling with age-related 
hypertension-linked vessel remodelling remains to be investigated.
One of the common forms of hypertension that is increasingly being diagnosed in elderly 
population is cor pulmonale or pulmonary arterial hypertension (PAH) [223–225]. PAH is a 
haemodynamic and pathophysiological condition defined by an increase in mean pulmonary 
artery pressure (mPAP) ≥25 mmHg at rest. It is the consequence of an increasing pulmonary 
vascular resistance (PVR) that leads to right ventricular (RV) overload, hypertrophy, 
reduction in cardiac output and eventually RV failure and death [226]. It is characterized by 
an intense and characteristic remodelling of small pulmonary arteries, due to structural and 
functional changes in endothelial, smooth muscle and adventitial fibroblast layers of the 
vessel wall [227]. One of the key environmental factors that cause extensive irreversible 
medial and adventitial thickening of vessel wall and muscularization of previously non-
muscularized distal vessels is chronic hypoxia (CH). Several studies have implicated ROS in 
acute hypoxic vasoconstriction and vascular remodelling associated with CH and a pivotal 
role of NADPH oxidase-derived ROS in this process is now well established. In one of the 
initial studies, Liu et al. [84] showed that CH-induced increase in superoxide anion 
production was attenuated in Nox2-null mice. This was associated with a decrease in 
pathological changes seen in CH-induced vascular remodelling such as mean RV pressure, 
medial wall thickening of small pulmonary arteries and right heart hypertrophy. They also 
linked increased ROS production to increased p47phox expression and activity, rather than 
increased mRNA expression levels of NADPH oxidase subunits, Nox2, p22phox, p40phox, 
Rac1 and Rac2 [84]. Later studies demonstrated that in the lung vasculature, Nox4-derived 
ROS play a crucial role in mediating PASMC and fibroblast proliferation-associated vascular 
remodelling in PAH. This was linked to increased Nox4 mRNA and protein expression 
[85,228–230]. It was suggested that the difference in localization of Nox2 and Nox4, to the 
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endothelial and smooth muscle cell layers respectively, is responsible for the differential role 
of Nox2 and Nox4 in hypoxia-induced pulmonary hypertension. Although it is known that 
RV function is the critical determinant of lifespan in patients with PAH, not much is known 
about the role Nox isoforms play in causing RV failure independent of an elevated 
pulmonary artery pressure. Using a pulmonary artery banding (PAB) model in mice, which 
is a surgical model of chronic progressive RV pressure overload not associated with 
structural alterations of the lung circulation, we recently showed PAB results in an increase 
in Nox4-derived ROS production, which is responsible for cardiac dysfunction and RV 
failure. We also showed that expression of antioxidant enzymes, SOD, catalase and Gpx did 
not change [45]. All of these studies elegantly link Nox-derived ROS to structural changes 
associated with PAH and subsequent RV failure, comparative studies in young and old 
animals are necessary to understand how these processes are modulated in aging heart.
Atrial fibrillation
AF is the most common type of cardiac arrhythmia. AF refers to abnormal rhythm of the 
heartbeat caused by perturbed electrophysiology of the myocardium. The incidence of AF 
increases quite dramatically with age (1.5 % at 50–59 years to 23.5 % at 80–89 years) [231] 
and even more so with prior history of cardiac surgery and cardiopulmonary diseases [232–
235]. A number of studies have shown that oxidative stress plays a vital role in the 
pathogenesis of AF [236–239]. It is also noteworthy that oxidative stress is also involved in 
the pathogenesis of several predisposing factors and conditions associated with AF. These 
include hypertension, CHD (chronic heart disease), obesity and diabetes, among many 
others. There is a large body of evidence showing the role that the NADPH oxidase family 
of enzymes plays in the development of AF. Both myocardial Nox2 and myocardial Nox4 
have been shown to participate in ROS-mediated effects in AF [38,39,86,240,241]. Initial 
studies in animal models suggested a Rac1-dependent effect of Nox-derived ROS leading to 
AF [86,242], which were supported by a number of clinical studies showing a correlation 
among Nox2 up-regulation, oxidative stress and AF [38,39,243]. Kim et al. [38] suggested 
that NADPH oxidase-derived ROS play an important role in the atrial oxidative injury 
associated with AF. In this study, they reported up-regulation of NADPH oxidase subunits 
p22phox, p47phox p67phox and Nox2, but not of Nox1 or Nox4, in tissue homogenates and 
isolated atrial myocytes from the right atrial appendage of patients undergoing cardiac 
surgery [38]. Importantly, Reilly et al. [241] suggested that an initial insult caused by Nox 
activation probably accounts for early development of AF, whereas ROS derived from 
mitochondria and uncoupled eNOS are involved in long-term AF. The change in the sources 
of ROS with atrial remodelling therefore could explain why statins are effective in the 
primary prevention of AF, but not in its management [241]. In vitro studies using HL-1 atrial 
myocytes have implicated Nox2 and Nox4 in TGFβ1-mediated myofibril degradation via 
calpain activation leading to calcium overload. Collectively, these were shown to elicit 
electrical and structural remodelling of cardiac tissue in AF [240,244]. Although these 
studies suggest a causal link between oxidative stress, the role of Nox and AF, the 
downstream signalling cascade by which atrial structural remodelling contributes to the 
pathogenesis of AF has not yet been described. A study by Adam et al. [245] demonstrated a 
marked up-regulation of CTGF, which is associated with increased fibrosis and tissue AngII 
concentration. With regard to an underlying mechanism, this study suggested that AngII up-
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regulated CTGF via activation of Rac1 and NADPH oxidase, leading to up-regulation of N-
cadherin and connexin43 (Cx43) and therefore contributing to structural remodelling 
associated with AF [245].
Nox therapeutics in treatment of CVDs
From the aforementioned studies, it is apparent that NADPH oxidase-derived ROS play a 
pivotal role in age-associated cardiovascular changes and CVDs. Therefore, Nox could be 
important drug targets for the treatment of atherosclerosis, hypertension, stroke, AF, diabetes 
and many other diseases of the elderly. The role of Nox as drug targets in CVDs has been 
extensively reviewed [246,247]. Despite a large armamentarium of drugs currently approved 
for specific therapy such as AngII receptor antagonists (azilsartan and benicar), renin 
inhibitor (aliskiren), calcium channel blockers (amlodipine), synthetic prostacyclin and its 
analogues (epoprostenol, treprostinil, beraprost, iloprost and selexipag), ET-1 receptor 
antagonists (bosentan, ambrisentan and macinentan) and type 5 phosphodiesterase (PDE5) 
inhibitors (sildenafil, tadalafil, vardenafil and riociguat) for PAH, blood thinners (aspirin, 
warfarin, dabigatran, rivaroxaban and apixaban) and dofetilide and dronedarone for AF, 
CVDs still contribute to a high level of mortality in the elderly. The beneficial effects of 
these drugs may, in part, come from their ability to reduce oxidative stress, either directly via 
attenuating the NADPH oxidase-derived ROS or indirectly by improving NO bioavailability 
[248,249]. Although antioxidants such as vitamins A, E and C, polyphenols and flavonoids 
have been used as therapeutic agents with some success to reduce oxidant stress and blood 
pressure [250], most of the large clinical trials have failed to demonstrate a beneficial 
cardiovascular effect [251,252]. Compared with the antioxidants, which degrade free radical 
intermediates and prevent further oxidation of molecules, inhibitors of Nox isoforms 
decrease the rate of enzymatic ROS formation. These inhibitors either modify Nox 
expression or target assembly and activation of Nox complexes, thereby reducing the 
immediate oxidant environment and suppressing ROS-induced signalling cascades.
Although some classical Nox inhibitors (AEBSF, apocynin, PR-39 and S17834) and two 
commonly used drugs, HMG-CoA reductase inhibitors (statins) and angiotensin receptor 
antagonists [ARBs (angiotensin II receptor blockers) and ACE (angiotensin-converting 
enzyme) inhibitors], are regularly being used in animal models and treatment therapy 
respectively, most of the currently available Nox inhibitors including the above-mentioned 
are not isoform-specific and may potentially affect both physiological and 
pathophysiological signalling pathways. Therefore, the development of selective and 
isoform-specific Nox inhibitors that preferably target only pathological Nox signalling has 
become a foremost objective for both academia and pharmaceutical companies. A number of 
different small-molecule inhibitors have become available that could become useful in their 
own right or by way of their derivatives [253–263]. Nox1/4 inhibitor GKT 136901 was 
reported to inhibit NADPH oxidase-dependent aortic ROS formation, attenuate CD44- and 
HA-dependent inflammatory cell recruitment and aortic lesion area in atherosclerotic lesions 
of ApoE−/− mice [264]. Similarly, GKT137831 inhibited ROS production and attenuated 
diabetes-induced macrophage infiltration, inflammation and fibrosis associated with 
atherosclerotic plaque formation in ApoE−/− mice as well as attenuated hypoxia-induced 
H2O2 release and improved indices of ventricular remodelling and pulmonary artery wall 
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thickening in a mouse hypoxia model of PAH [211,265]. Like the first-generation GKT 
inhibitor, issues of Nox specificity are still a concern with regard to untoward and off-target 
effects of these drugs. Novel approaches and rational drug design strategies have yielded 
isoform selectivity for Nox2 and been discussed in greater detail [107,108,247,258,266]. 
Assuredly with these innovative approaches, new isoform-specific Nox therapeutics are 
expected to gain greater traction. That said, peptidic inhibitors still appear to offer the 
greatest level of Nox selectivity [267–270] and have exhibited high levels of potency in cell-
free and whole-cell assays. For this reason, they have been widely employed in animal 
studies. Admittedly, an inherent concern in the pharmaceutical industry regarding oral 
bioavailability of these potential therapeutics has stunted development, in spite of the 
potential for alternative modes of delivery and stabilization to increase clinical application 
[107,271].
CONCLUSIONS AND PERSPECTIVES
A higher level of care, treatment options and better socioeconomic conditions have resulted 
in a dramatic increase in the quality and lifespan of the elderly population with 
cardiovascular complications over the last half-century. Since the free radical theory of aging 
was first proposed, tremendous progress has been made to identify and understand the 
molecular mechanisms involved in aging and age-related CVDs. A seminal role of Nox in 
CVD is quite evident. Despite these advances, manifestation of combined aetiologies (co-
morbidities) together with age-related changes further complicates our understanding of the 
pathophysiological and pathobiological factors contributing to decline in the older patient. 
Indeed, much more work needs to be done to determine whether there is a unified effect of 
ROS on longevity and CVD. That is, whether specific Nox isoforms are responsible for 
modulating CVD and the biology of the aging process and whether these are both modulated 
by a common gene or set of longevity genes are yet to be fully appreciated. Furthermore, 
with Nox-targeted therapies showing promising results in animal models and pre-clinical 
trials, it is possible that, in the near future, we may be able to adapt these interventions to 
further improving cardiovascular health and/or slow the aging process.
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Abbreviations
AAC aortic abdominal constriction
AEBSF 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride
AF atrial fibrillation
AKT synonym for Protein kinase B
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AngII angiotensin II
ApoE apolipoprotein E
CAD coronary artery disease
CCN1 or CYR61 cysteine-rich angiogenic inducer 61
FGF fibroblast growth factor
CD44 cluster of differentiation 44
CH chronic hypoxia
CTGF connective tissue growth factor
CVD cardiovascular disease
DUOX dual oxidase
eNOS endothelial nitric oxide synthase
ERK extracellular-signal-regulated kinase
ET-1 endothelin-1
FGF-R fibroblast growth factor receptor
FOXO3 forkhead-box protein O3
GKT GenKyotex
Gpx glutathione peroxidase
HA hyaluronic acid
HMG-coA 3-hydroxy-3-methyl-glutaryl-coenzyme A
IGF-1 insulin-like growth factor
IGF-1R IGF-1 receptor
JNK c-Jun N-terminal kinases
KL-VS variant of Klotho
LDL low-density lipoprotein
LID liver IGF-1-deficiency
MAPK mitogen-activated protein kinase
Mdm2 mouse double minute 2 homolog
MK2 mitogen-activated protein kinase-activated protein kinase 2
MMP matrix metalloproteinase
mTOR mammalian target of rapamycin
NOS nitric oxide synthase
Nox NADPH oxidase(s)
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Nrf nuclear factor erythroid-derived 2-related factor
PAB pulmonary artery banding
PAH pulmonary arterial hypertension
PASMC pulmonary artery smooth muscle cell
Pin1 prolyl isomerase 1
PKA protein kinase A
PKC protein kinase C
PKCδ Protein Kinase C delta
Poldip2 polymerase (DNA-directed), delta interacting protein 2
Shc src homology 2 domain containing
PR-39 proline-arginine (PR)-rich antibacterial peptide
PTB phospho tyrosine binding
RAAS renin–angiotensin–aldosterone system
Ras Rat sarcoma
RING Really Interesting New Gene
ROS reactive oxygen species
RV right ventricular
S17834 1,4-dimethyl-2,3,5,6-tetraiodobenzene
SHR spontaneously hypertensive rats
Sir2 silent information regulator 2
SKN-1 protein skinhead 1
SMC smooth muscle cell
SOD superoxide dismutase
TGFβ transforming growth factor β
Trx2 Thioredoxin2
VSMC vascular smooth muscle cell
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Figure 1. Prominent redox-sensitive signalling pathways involved in aging
Schematic representation of known redox-sensitive signalling pathways which regulate 
cellular aging and age-related CVDs. Arrows denote positive activation of downstream 
targets. Blunt-ended arrow denotes inhibitory effects. Dashed arrow denotes cross-talk 
between pathways. Secreted Klotho prolongs lifespan by increasing the expression of 
antioxidant genes via Nrf-1/2 or by inhibiting IGF-1 signalling. Binding of growth 
hormones, such as IGF-1 to their respective receptors or oxidative stress leads to 
autophosphorylation of β-subunits on the IGF-1R, leading to subsequent activation of 
PI3K/Akt pathway. Akt-mediated phosphorylation of FOXO3 results in nuclear exclusion 
and inhibition of FOXO3-mediated transcription of target antioxidants, such as MnSOD and 
Gpx. Oxidative stress induces phosphorylation and translocation of p66Shc via PKCβ and 
Pin1 to the mitochondrial inner membrane leading to cytochrome c-mediated apoptosis. 
ROS also causes post-translational modification of p53 resulting in its activation triggering 
p21cip-mediated cell senescence. Akt activation or p53-induced transcriptional activation of 
Mdm2 leads to ubiquitination-dependent degradation of FOXO3. Abbreviations: PI3K, 
phosphoinositide 3-kinase; s-Klotho, secreted Klotho.
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Figure 2. Effects of Nox-derived ROS on redox-sensitive longevity signalling in the vessel wall
Summary of the effects of hypertension, atherosclerosis and PAH on age-related redox-
sensitive signalling pathways linked to the different vascular cells comprising the vessel wall 
(intima: endothelial cells; media: VSMCs; adventitia: fibroblasts/myofibroblasts) as a 
consequence of Nox-derived ROS. Arrows depict either increased or decreased protein 
expression or signalling pathway activation. A question mark (?) depicts a potential effect 
wherein more conclusive evidence is required to fully support the observations in the 
literature.
Sahoo et al. Page 35
Clin Sci (Lond). Author manuscript; available in PMC 2016 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
